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Contrast Enhanced Ultrasound in CT-undetermined 
Focal Liver Lesions
entiating small cysts from malignant lesions, due 
to partial volume [5]. Hemangiomas are the most 
common solid focal liver lesions with a preva-
lence of 7–21 %. Focal nodular hyperplasia (FNH) 
is the second most commonly occurring benign 
focal liver lesion, with a prevalence of 3 % [4]. 
Other benign focal liver lesions are adenomas 
and abscesses. Focal fatty sparing and focal fatty 
infiltration are also commonly found in the liver. 
Even though they are not focal lesions, they can 
represent pseudo lesions on CT or ultrasound; 
also the infrequent third inflow can represent a 
pseudo lesion on CT [4].
Ultrasound has a low sensitivity in diagnosis of 
FLLs in comparison with other diagnostic modal-
ities such as CT [4]. Patients are therefore usually 
examined with CT or magnetic resonance imag-
ing (MRI) [4]. Contrast agents used in CT and MRI 
are known to be nephrotoxic and are contraindi-
Introduction
▼
Detection and characterisation of benign and 
malignant focal liver lesions (FLLs), often as inci-
dental findings, are a common radiological task. 
Volk et al. [1] reported incidental FLLs in 6 % of 
1 892 patients scanned by computed tomography 
(CT).
FLLs are commonly found in patients with and 
without cancer, and have been reported to be 
present in up to 50 % of autopsies [2]. Liver metas-
tases are found in 25–50 % of patients with non-
haematological malignant conditions, often in 
colorectal cancer, lung cancer, breast cancer and 
pancreatic cancer [3]. Approximately 25–50 % of 
small ( < 2 cm) FLLs in oncological patients are of 
a benign nature [4].
Cysts are the most commonly found FLLs, and CT, 
in contrast to ultrasound, has difficulties differ-
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Abstract
▼
Purpose: The purpose of this study was to 
examine the diagnostic accuracy of CEUS in the 
diagnosis of focal liver lesions, which were unde-
termined at CT scan.
Materials and Methods: From January 2010 to 
December 2010, patients with CT-undetermined 
focal liver lesions were included in this study. A 
total of 78 patients were evaluated: 41 men and 
37 women, mean age 61.8 years; age range 30–91 
years. All patients were examined with GE LOGIQ 
9E ultrasound scanners with contrast-specific 
software, and SonoVue intravenous bolus. The 
standard of reference was composite consisting 
of: percutaneous biopsy, surgical resection, PET/
CT and clinical follow-up.
Results: The 78 included patients had 163 
undetermined focal liver lesions, mean size 
1.1 cm, range 0.1–5.3 cm. There were 18 malig-
nant and 145 benign liver lesions, as defined 
by the standard of reference. In differentiat-
ing between benign vs. malignant CEUS dem-
onstrated sensitivity, specificity, PPV, NPV and 
accuracy of 94.4 % (95 % CI: 56.3–99.5 %), 99.3 % 
(95 % CI: 94.9 –99.9 %), 94.4 % (95 % CI: 56.3–
99.5 %), 99.3 % (95 % CI: 94.9–99.9 %) and 98.7 % 
(95 % CI: 94.9–99.7 %), respectively. If the CEUS-
inconclusive results were assumed to indicate 
malignancy, then sensitivity, specificity, PPV, 
NPV and accuracy would be 95.8 % (95 % CI: 66.4–
99.6 %), 98.6 % (95 % CI: 94.4–99.7 %), 92.0 % (95CI: 
65.1–98.6 %), 99.3 % (95 % CI: 95.0–99.9 %), 98.2 % 
(95 % CI: 94.4–99.5 %).
Conclusion: The results of this study showed a 
high diagnostic accuracy for CEUS in undeter-
mined focal liver lesions found by CT. Due to a 
high diagnostic accuracy of CEUS in this study, it 
was cautiously concluded that CEUS is useful in 
differentiating between malignant and benign 
focal liver lesions in clinical practice.
THIEME
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cated in patients with renal insufficiency and present a risk of 
inducing contrast-nephropathy [6]. CT is more expensive and 
requires more resources than contrast-enhanced ultrasound 
(CEUS). Another disadvantage of CT is its use of ionizing radia-
tion [6]. MRI is contraindicative in patients with claustrophobia 
and patients with pacemakers or metal implants [6]. SonoVue is 
considered safe to use in patients with renal insufficiency, 
because SonoVue is not nephrotoxic [6].
The diagnostic advantages of CEUS in the diagnosis of FLLs have 
been reported in the literature, and the use of CEUS is recom-
mended in undetermined CT findings [7, 8]. Studies have shown 
that CEUS has a sensitivity of 85–90 % and a specificity of 
86–90 %, in differentiating between benign and malignant FLLs 
[7, 9–11]. Sensitivity and specificity of CEUS in CT-undetermined 
FLLs have not been fully studied, and have only been shown use-
ful in a few studies [11, 12]. In addition, the clustered nature of 
the liver lesions has not been taken into account in the previous 
studies.
An accurate and safe diagnostic method with few side effects is 
essential for satisfactory patient outcome and management. 
Therefore, it is of clinical importance to have a high diagnostic 
accuracy of CEUS in CT-undetermined FLLs.
The purpose of this study was to examine the diagnostic accu-
racy of CEUS in the diagnosis of focal liver lesions, which were 
undetermined in the initial CT scan.
Materials and Methods
▼
The design of this study follows the Standards for Reporting of 
Diagnostic Accuracy (STARD) in order to achieve the methodo-
logical quality that is required in the reporting of diagnostic 
accuracy [13]. The study was approved by the National Data Pro-
tection Agency (journal nr. 2013-41-1928). Patient lists were 
obtained through the Radiology Information System (RIS) and 
Picture Archiving and Communications System (PACS).
Population
This study retrospectively examined all CT studies performed 
from January 2010 to December 2010 (n = 920) by a single cen-
tre. Patients with at least one CT-undetermined FLL who were 
also referred to CEUS were included (n = 84). 3 patients with 5 
FLLs were excluded because CEUS was not performed for various 
reasons, such as patients not showing up or being unwilling to 
do the exam with contrast. 3 patients with 7 FLLs were inconclu-
sive on CEUS and were excluded from the primary analyses, but 
included in the sensitivity analyses. Thus 78 patients with 163 
FLLs, 41 men and 37 women, with a mean age 61.8 years (age 
range 30–91, SD 14.2), comprised the study population. The 
inclusion and exclusion criteria are shown in the flow dia-
gram,  ●▶	 Fig. 1.
Undetermined FLLs in CT were defined as lesions, including 
cysts in the liver, not characterised by the imaging modality, 
requiring further imaging, histology or clinical follow-up.
Diagnostic materials and equipment
All patients with CT-undetermined FLLs were examined at the 
same centre with multi-slice scanners (Brilliance CT 64-channel, 
Philips, The Netherlands). All ultrasound and CEUS examina-
tions were performed by one of the 2 identical high-end scan-
ners LOGIQ E9 (General Electric Healthcare, USA) with 
contrast-specific software, using pulse inversion harmonic 
imaging, with low mechanical index (MI). SonoVue (Bracco 
Imaging, Italy) was used as the ultrasound contrast medium. 
SonoVue, which is a second generation contrast medium, con-
sists of stabilised micro bubbles of sulphur hexafluoride with a 
diameter of 2.5 µm, in saline solution [14].
Contrast-enhanced ultrasound
All patients referred to CEUS were scanned with B-mode ultra-
sound to localise the FLLs. Intravenous access was done using a 
winged infusion set where a 1.2 ml bolus of SonoVue was 
injected, followed by 5 ml of saline solution. With the FLLs in the 
field of view, the vascular distribution of SonoVue in the arterial, 
portal venous phases and the late phase was recorded in 15 s 
cine clips. The different phases were defined as follows:
▶ Arterial phase: approx. 10–35 s after bolus
▶ Portal venous phase: approx. 35–120 s after bolus
▶ The late phase:  > 120 s after bolus
5 radiologists performed the CEUS examinations. Their experience 
in performing and interpreting CEUS ranged from less than one and 
up to 6 years of experience, and when needed, the less experienced 
radiologist was supervised by the more experienced. The CEUS 
examinations were interpreted primarily at the bedside and, when 
needed, at PACS work stations. This study did not distinguish 
among the different radiologists and their level of experience.
Fig. 1 Flow diagram 
showing the inclu-
sions and exclusions 
criterion.
920 patients examined by CT
84 patients with 177 CT
inconclusive FLLs
3 patients with a total of 5
FLLs were excluded
because no CEUS
3 patients with a total of 7
FLLs were excluded
because of inconclusive
CEUS
2 other FLLs in one of these
patients had missing
percutaneous biopsy
Study population:
78 patients with 163
CT inconclusive FLLs
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Diagnostic criteria for CEUS
The radiologists’ final written report on CEUS examinations was 
used to establish the diagnosis of the FLLs. The diagnoses of the 
FLLs by CEUS were based on vascular patterns of SonoVue in dif-
ferent phases, also known as wash-in and wash-out, in contrast 
to adjacent normal liver parenchyma, as defined by Guidelines 
and Good Clinical Practice Recommendations for Contrast-
Enhanced Ultrasound [8], see  ●▶	 Tables 1 and  ●▶	 2. FLLs with a 
wash-out pattern in the portal venous phase and the late phase 
were interpreted as malignant. FLLs with no wash-out patterns 
were interpreted as benign.
Reference standard
Histological data for the 78 included patients were searched to 
establish the final diagnosis of the 163 FLLs. Histological data 
from percutaneous biopsy or surgical resection were considered 
the gold standard in 7 cases. When histology was not available, 
imaging and one-year clinical follow-up were used in 156 cases. 
Imaging follow-up was performed using CT and PET/CT, whereas 
CEUS was used only for benign lesions. None of the malignant 
FLLs had ultrasound or CEUS as the standard of reference, 
see  ●▶	 Table 3. The reports in RIS/PACS, written by radiologists, 
were used for imaging follow-up. Clinical follow-up was estab-
lished using the hospital electronic medical records. In this 
study, the reference standard was composite, consisting of his-
tology from percutaneous biopsy or surgical resection, imaging, 
and clinical follow-up.  ●▶	 Fig. 2 shows the work flow diagram for 
establishing the reference standard.
Statistical analysis
Data were analysed descriptively according to data type: cate-
gorical variables were displayed by frequencies and respective 
percentages, continuous variables by means and standard devia-
tions or medians and ranges, depending on whether continuous 
variables were roughly symmetrically distributed as judged vis-
ually by means of histograms and approximating normal distri-
butions. The diagnostic accuracy of CEUS was calculated on a 
per-lesion basis. Sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were calculated with 
95 % confidence intervals (95 % CI) using standard errors allow-
ing for intragroup correlation due to the clustered structure of 
FLLs. Malignant and benign lesions, which were classified cor-
rectly compared to the composite reference standard, were 
assessed as true positive and true negative, respectively. Lesions, 
which were inconclusive according to CEUS, were left out of the 
primary analyses. In sensitivity analyses, we studied 2 strate-
gies: (a) classifying those inconclusive lesions in case of malig-
nancy as false negative and benignity as false positive (worst 
case scenario); (b) classifying all lesions which were inconclu-
sive according to CEUS as positive (clinically conservative strat-
egy) [15]. Statistical analyses were done using Stata IC 14.1 
(StataCorp. LP, College Station, TX 77845, USA).
Results
▼
We included 78 patients with 163 undetermined FLLs in this 
study. Multiple FLLs in a patient were counted as 5 FLLs, because 
the exact numbers of FLLs in these patients were not available. 
In 78 patients, 18 % had multiple FLLs, 1 % had 4 FLLs, 8 % had 3 
FLLs, 18 % had 2 FLLs and 55 % had a single FLL. The 163 CT-unde-
termined FLLs were examined by CEUS and compared with the 
reference standard. CEUS found 17 true positive, 144 true nega-
tive, one false positive and one false negative FLL. CEUS were 
inconclusive for 7 FLLs in 3 patients. 2 of these patients had one 
FLL each and one had 5 FLLs.
All malignant FLLs, in 78 patients, were confirmed by the stand-
ard of reference as liver metastases. 9 metastases were found in 
7 colorectal cancer patients. 3 metastases were found in one 
patient with uterine cancer. One metastasis was found in one 
lung cancer patient. 5 metastases were found in one patient 
diagnosed with prostate cancer. In the 3 cases where CEUS was 
inconclusive, one patient had one FNH determined by CT. One 
patient had one metastasis and one had 5 metastases deter-
mined by histology. The most frequent benign FLLs were cysts. 
CEUS was unable to establish the differential diagnoses for the 
Table 1 Diagnostic criteria of CEUS for typical malignant FLLs in non-cirrhotic liver according to EFSUMB guidelines.
FLL Arterial phase Portal phase Late phase
HCC Hyper-enhancing Iso-enhancing Hypo-enhancing/Slight or moderate wash-out
Metastasis Rim-enhancement Hypo-enhancing/Wash-out Hypo-enhancing/Wash-out
Metastasis Enhancement Hypo-enhancing/Wash-out Hypo-enhancing/Wash-out
Cholangiocarcinoma Rim-enhancement Hypo-enhancing/Wash-out Hypo-enhancing/Wash-out
Table 2 Diagnostic criteria of CEUS for typical benign FLLs in non-cirrhotic liver according to EFSUMB guidelines.
FLL Arterial phase Portal venous phase Late phase
Hemangioma Peripheral-nodular or no central enhancement Partial	or	complete	centripetal	filling Complete enhancement
FNH Early hyper-enhancing, spoke-wheel pattern Hyper-enhancing Iso/hyper-enhancing
Focal	fatty	infiltration/Sparing Iso-enhancing Iso-enhancing Iso-enhancing
Simple cyst Non-enhancing Non-enhancing Non-enhancing
Adenoma Hyper-enhancing Hyper-enhancing Iso- or slightly hypo-enhancing
Abscess Rim-enhancement Hyper/Iso-enhancing rim Hypo-enhancing rim
Table 3 Distribution of benign and malignant FLLs as found by the stand-
ards of reference.
Standard of Reference Malignant Benign FLLs
Clinical follow-up 4 65 69 (42.33 %)
CT 10 51 61 (37.42 %)
Histopathology 3 4 7 (4.29 %)
Ultrasound 0 1 1 (0.61 %)
CEUS 0 24 24 (14.72 %)
PET/CT 1 0 1 (0.61 %)
Total 18 145 163 (100.00 %)
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Table 4	 Differential	diagnoses	of	the	FLLs	as	found	by	the	standards	of	
reference.
FLL Frequnecy
Cyst 64 (39.26 %)
Hemangioma 36 (22.09 %)
Metastasis 18 (11.04 %)
FNH 1 (0.61 %)
Biliary hamartoma 1 (0.61 %)
Focal	fatty	infiltration 3 (1.84 %)
Benign	non-specific 40 (24.54 %)
Total 163 (100.00 %)
remaining 40 benign FLLs, see  ●▶	 Table 4. The 78 included patients 
had 163 FLLs, mean size 1.1 cm; range 0.1–5.2 cm, SD 0.73 cm.
CEUS found 17 true positive FLLs, with a mean size of 1.3 cm; 
range 0.8–1.8 cm, SD 0.39 cm. The 144 true negative FLLs found 
by CEUS had a mean size of 1.1 cm, range 0.1–5.2 cm, SD 0.79 cm. 
One 1.5 cm FLL was false positively diagnosed by CEUS as a 
metastasis. This FLL was diagnosed by histology as biliary 
hamartoma (von Meyenburg complex). One 0.7 cm FLL was 
wrongly diagnosed by CEUS as benign non-specific, but imaging 
follow-up done by PET/CT, found this FLL to be a metastasis.
Sensitivity, specificity, PPV, NPV and accuracy with 95 % CI of 
CEUS were 94.4 % (95 % CI: 56.3–99.5 %), 99.3 % (95 % CI: 94.9–
99.9 %), 94.4 % (95 % CI: 56.3–99.5 %), 99.3 % (95 % CI: 94.9–99.9 %), 
and 98.7 % (95 % CI: 94.9–99.7 %), respectively, see  ●▶	 Table 5. Sen-
sitivity analyses (a) where classifying 3 inconclusive lesions in 
case of malignancy as false negative and benignity as false posi-
tive are shown in  ●▶	 Table 6; these indicated a significant drop in 
sensitivity and PPV from 94.4 to 70.8 % and from 99.3 to 89.5 %, 
respectively. Sensitivity analyses (b) classifying all lesions that 
were inconclusive according to CEUS as positive are shown 
in  ●▶	 Table 7, suggesting a smaller increase in sensitivity by 1.4 % 
and a decrease in PPV by 2.4 %. No side effects were reported 
from the use of SonoVue.
Discussion
▼
The primary analyses in this study showed a high diagnostic 
accuracy for CEUS in distinguishing between malignant and 
benign FLLs, which were undetermined by CT. The results of our 
study showed that CEUS was capable of correctly diagnosing 17 
malignant FLLs among 18 with a relatively narrow 95 % CI. Our 
study also showed that CEUS was capable of correctly diagnos-
ing 144 FLLs from 145 benign FLLs with a very narrow 95 % CI. 
Table 5	 Primary	analysis:	sensitivity,	specificity,	PPV,	NPV,	accuracy	and	
95 % CI of CEUS in CT undetermined FLLs.
Parameter Point Estimate 95 % CI
Sensitivity 94.4 % 56.3–99.5 %
Specificity 99.3 % 94.9–99.9 %
PPV 94.4 % 56.3–99.5 %
NPV 99.3 % 94.9–99.9 %
Accuracy 98.7 % 94.9–99.7 %
Table 6 Sensitivity analysis (a) including the inconclusive CEUS results – 
classifying 6 malignant lesions and one benign lesion in 3 patients as false 
negative	and	false	positive,	respectively.	Sensitivity,	specificity,	PPV,	NPV,	
accuracy and 95 % CI of CEUS in CT-undetermined FLLs.
Parameter Point Estimate 95 % CI
Sensitivity 70.8 % 25.7–94.5 %
Specificity 98.6 % 94.4–99.7 %
PPV 89.5 % 55.7–98.3 %
NPV 95.4 % 81.8–98.9 %
Accuracy 94.7 % 83.9–98.4 %
Fig. 2 Flowchart showing the work up of refer-
ence standard.
Cyst = imaging
or clinical
follow-up
Solid lesion =
imaging and
clinical
follow-up
Histopathology
or imaging
follow-up
MalignantBenign
CEUS
CT
inconclusive
FLLs
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The 0.7 cm false negative FLL was diagnosed by PET/CT as a 
metastasis and was located in segment VI of the liver. It is diffi-
cult to determine the exact cause of the false negative CEUS find-
ing. It is well known that ultrasound is operator-dependent. 
Therefore, it is possible that the false negative FLL is due to inad-
equate visualisation of the segment VI of the liver.
CEUS uses the same contrast dynamics as CT, requires fewer 
resources and does not use ionizing radiation. Unlike iodinated 
CT contrast agents, SonoVue remains in the blood vessels, due to 
the size of the microbubbles [6, 7]. This true blood pool charac-
teristic combined with the dynamic picture acquisition and har-
monic imaging technique makes CEUS capable of detecting even 
the smallest amount of contrast agent in the capillaries of the 
FLLs, in the arterial, portal venous and late venous phases. Single 
phase CT is inadequate in visualising the 3 perfusion phases. CT 
can have difficulties visualising the tumour perfusion of the FLLs 
due to incorrect timing between contrast injection and picture 
acquisition [6, 7]. Small FLLs ≤ 2 cm are often difficult to diagnose 
correctly by CT and are described by radiologists as undeter-
mined. It is commonly known that these difficulties are caused 
by partial volume averaging, which makes correct measure-
ments of Hounsfield units difficult [12]. The results of this study 
showed that most FLLs were  ≤ 2 cm, in accordance with the lit-
erature. Differentiation of FLLs with CEUS are based on uptake 
and wash-out patterns compared with the normal liver paren-
chyma, see  ●▶	 Tables 1, 2 and the portal and late venous phases 
are especially important for the differentiation between malig-
nant and benign lesions [7–11]. The minute differences between 
the different FLLs in the arterial phase make their differentiation 
somewhat difficult, and the differentiation is dependent on the 
experience of the ultrasound operator. However, the most 
important criteria for distinguishing between malignant and 
benign FLLs are the portal and late venous phases, where the 
malignant FLLs have a wash-out pattern and the benign FLLs are 
hyper/isoechoic, see  ●▶	 Fig. 3, 4. The high sensitivity of ultra-
sound with only a small amount of contrast agent is mainly due 
to high spatial resolution of ultrasound, combined with a high 
contrast resolution from the microbubbles non-linear harmonic 
frequencies and high temporal resolution [16]. Contrast agents 
like SonoVue are non-nephrotoxic and considered safe with few 
side effects [8]. Patients referred to CEUS with CT-undetermined 
FLLs are often fearful of malignancy. The interpretation method 
of CEUS, which is often performed at the bedside, makes fast and 
accurate diagnoses possible, so that patients with benign FLLs 
can be excluded, avoiding unnecessary and demanding ionizing 
radiological follow-up, biopsy, and consequent complications.
Previous studies have shown that CEUS may have a high diag-
nostic value in differentiating FLLs [7, 9, 10, 17–19]. In a recently 
published study, CEUS showed a high diagnostic accuracy in CT-
undetermined FLLs [20]. The results of our study, however, are 
not directly comparable with these studies. The FLLs in our 
study were all undetermined at the initial CT. Unlike other stud-
ies, we included cysts, focal fatty infiltrations, focal fatty spar-
ings and hemangiomas in order to better estimate the overall 
diagnostic accuracy of CEUS in clinical practice. Our study 
includes more patients with more undetermined FLLs than pre-
vious studies. The diagnostic method of CEUS in our study was 
Table 7 Sensitivity analysis (b) including the inconclusive CEUS results – 
classifying	7	lesions	in	3	patients	as	positive.	Sensitivity,	specificity,	PPV,	NPV,	
accuracy and 95 % CI of CEUS in CT-undetermined FLLs.
Parameter Point Estimate 95 % CI
Sensitivity 95.8 % 66.4–99.6 %
Specificity 98.6 % 94.4–99.7 %
PPV 92.0 % 65.1–98.6 %
NPV 99.3 % 95.0–99.9 %
Accuracy 98.2 % 94.4–99.5 %
Fig. 3 a CT scan with undetermined FLL. b Same 
FLL on B-mode ultrasound. c Same FLL on CEUS 
with isoenhancing contrast pattern in late venous 
phase. The FLL was benign and characterised as 
FNH.
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performed at the bedside with cine loops option, for on-site 
review and consultation with more experienced radiologists. 
We believe that the reading method in our study, which also 
allows for multiple contrast agent administrations, can improve 
the overall diagnostic accuracy of CEUS in CT-undetermined FLLs.
The primary analyses of our study have some limitations regard-
ing the diagnostic value of CEUS: the exclusion of CEUS-incon-
clusive FLLs has artificially increased the sensitivity and PPV, 
whereas sensitivity analyses (a) have decreased the values con-
siderably. We believe that approach (a) is too conservative and 
that analyses (b) are more useful in clinical practice as inconclu-
sive CEUS is preferably assumed to indicate malignancy in order 
to proceed with percutaneous biopsy. Furthermore, our study 
also showed that, if a CT-undetermined FLL is diagnosed by CEUS 
as benign, it is safe to consider it as such. Our study has limita-
tions regarding the standard of reference. Histological references 
were only available for 7 CEUS-conclusive FLLs, thus most FLLs 
were confirmed by clinical follow-up or imaging follow-up like 
CT, ultrasound, CEUS and PET/CT. It can be poor research practice 
to use an initially inconclusive modality like CT or ultrasound/
CEUS as a standard of reference. We believe that this approach is 
useful because if a FLL has not grown in size for at least one year, 
it is safe to consider it as benign. A study from Tan et al. also used 
a one-year follow-up and if a liver lesion remained stable, the 
lesion was considered benign [21].
Furthermore, ultrasound/CEUS was not used as its own standard 
of reference for any malignant FLLs. The use of CT for imaging 
follow-up indicates that most patients with malignant FLLs were 
known to have a malignant condition. In our study, we did not 
distinguish between the experience of the radiologists who 
interpreted the CEUS studies, preventing us from examining 
inter-rater variations. The diagnostic accuracy is higher in our 
study because all CEUS studies were interpreted via consensus 
with the most experienced radiologist. This study had some 
minor limitations regarding the population because we did not 
consider the inclusion or distribution of symptomatic vs. asymp-
tomatic patients. The low prevalence of malignant FLLs can be 
interpreted as a low prevalence of symptomatic patients in our 
study population. Patients with several and multiple FLLs were 
regarded as having 5 FLLs, because the exact number of FLLs per 
patient was not available from the CT interpretations. This 
approach must have reduced the number of benign FLLs. In our 
study, we excluded 2 FLLs in one patient due to lack of biopsy. 
Considering the false positive nature of the remaining FLL in one 
patient, it can be argued that this approach has increased the 
specificity and NPV of CEUS. The final diagnosis of the remaining 
FLL, using histology, was biliary hamartoma, see  ●▶	 Fig. 5. Few 
case studies exist regarding the CEUS characteristics of biliary 
hamartoma, and there seem to be contradictory reports regard-
ing the portal and late venous phases [17, 22, 23]. The diagnostic 
values of CEUS in our study were calculated on a lesion by lesion 
basis and therefore cannot be directly transferred to a patient-
by-patient basis in clinical practice.
Even though our study has some limitations, CEUS showed a 
high diagnostic accuracy in distinguishing between malignant 
and benign FLLs that were undetermined at the initial CT. There-
fore, we cautiously conclude that the results of this study are 
useful in clinical practice.
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Fig. 4 a CT scan with undetermined focal liver 
lesion (FLL). b Same FLL on B-mode ultrasound.  
c Same FLL on contrast enhanced ultrasound 
(CEUS) with washout pattern in late venous phase. 
The FLL was malignant and characterised as a 
metastasis.
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Fig. 5 a CT scan with undetermined focal liver 
lesion (FLL). b Same FLL on B-mode ultrasound.  
c Same FLL on contrast enhanced ultrasound 
(CEUS) with washout pattern in portal and late 
venous phase, wrongly diagnosed by CEUS as 
metastasis. Histopathology showed biliary hamar-
toma.
